“For people living with obesity, weight loss is only one part of the story. They face an increased risk of developing serious conditions driven by obesity and associated metabolic dysfunction, including metabolic liver disease, type 2 diabetes, and cardiovascular disease. There is an urgent need for treatments that go beyond weight loss to also address these related conditions,” Dr Lee Kaplan, M.D., Ph.D., Director of The Obesity and Metabolism Institute, Boston, MA, USA, Chair of the SYNCHRONIZE program executive committee said. “I am delighted to see that these data reveal that the glucagon/GLP-1 dual agonism of survodutide offers a promising approach for people with obesity, and for those with obesity-associated metabolic liver diseases including MASLD and MASH.”